ERBB2 and triple-negative breast carcinoma: Triple-negative breast cancer (TNBC) accounts for 15%–20% of all breast cancers and is characterized by a lack of specific molecular biomarkers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) [1].